Ultime notizie per OncoCyte (NASDAQ:OCX) Azioni

OncoCyte

OncoCyte Corporation Common Stock

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.

OncoCyte Corp

Bernstein analyst Laurent Yoon maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Market Perform and raises the price target from $625 to $780.

News

Price Target

Analyst Ratings

NFLX

Bernstein Maintains Market Perform on Netflix, Raises Price Target to $780

Canaccord Genuity analyst Maria Ripps maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Hold and raises the price target from $750 to $760.

Canaccord Genuity Maintains Hold on Netflix, Raises Price Target to $760

Piper Sandler analyst Nathan Race maintains Old Second Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSBC#NASDAQ">OSBC</a>) with a Overweight and raises the price target from $22.5 to $23.

OSBC

Piper Sandler Maintains Overweight on Old Second Bancorp, Raises Price Target to $23

U.S. stocks traded mixed this morning, with the Dow Jones falling over 100 points on Friday.
Following the market opening Friday, the Dow traded down 0.35% to 43,086.52 while the NASDAQ rose 0.73% to 18,507.31. The S&amp;P 500 also rose, gaining, 0.26% to 5,856.65.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a>
Leading and Lagging Sectors Communication services shares jumped by 1.4% on Friday.
In trading on Friday, energy shares fell by 0.6%.
Top Headline
Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported stronger-than-expected third-quarter financial results, posting revenue of $9.825 billion, up 15% year-over-year, versus market estimates of $9.769 billion.
The company ended the third quarter with 282.72 million global paid subscribers, up 14.4% year-over-year.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Catheter Precision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NASDAQ">VTAK</a>) shares shot up 249% to $1.54.</li>
<li>Shares of Bright Minds Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) got a boost, surging 133% to $50.66. The company announced a $35 million non-brokered private placement.</li>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares were also up, gaining 96% to $15.55 after the company announced it filed a form RW and will not pursue a public offering at this time.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares dropped 38% to $0.4301.</li>
<li>Shares of Orgenesis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) were down 34% to $2.1100.</li>
<li>NuZee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) was down, falling 31% to $1.5950.</li>
</ul>
Commodities In commodity news, oil traded down 1.5% to $69.59 while gold traded up 0.8% at $2,730.00.
Silver traded up 2.9% to $32.690 on Friday, while copper rose 1.3% to $4.3815.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.1%, Germany's DAX rose 0.2% and France's CAC 40 climbed 0.2%. Spain's IBEX 35 Index fell 0.2%, while London's FTSE 100 fell 0.8%.
Construction output in the Eurozone fell by 2.5% year-over-year in August compared to a revised 2.3% decline in the previous month. The current account surplus in the Eurozone increased to €35.2 billion in August from €26.8 billion in the year-ago period.
Asia Pacific Markets
Asian markets closed higher on Friday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index climbing 3.61%, China's Shanghai Composite Index gaining 2.91% and India's BSE Sensex gaining 0.27%.
Economics
<ul>
<li>U.S. housing starts fell by 0.5% from the previous month to an annualized rate of 1.354 million units in September.</li>
<li>Building permits declined by 2.9% to an annual rate of 1.428 million in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41402086/wall-streets-most-accurate-analysts-give-their-take-on-3-financials-stocks-delivering-hi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financials Stocks Delivering High-Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

DRUG

NKGN

NUZE

ORGS

SOBR

VTAK

Dow Falls Over 100 Points; Netflix Posts Upbeat Results

Piper Sandler analyst Stephen Scouten maintains Bank OZK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>) with a Overweight and raises the price target from $58 to $63.

Piper Sandler Maintains Overweight on Bank OZK, Raises Price Target to $63

Canaccord Genuity analyst Brian McNamara maintains Hillman Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) with a Buy and maintains $13 price target.

HLMN

Canaccord Genuity Maintains Buy on Hillman Solns, Maintains $13 Price Target

Argus Research downgrades Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) from Buy to Hold.

Downgrades

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Argus Research Downgrades Elevance Health to Hold

Canaccord Genuity analyst Maria Ripps maintains Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) with a Hold and raises the price target from $11 to $13.

Canaccord Genuity Maintains Hold on Viant Technology, Raises Price Target to $13

Autoliv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) shares are <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41398774/autoliv-financial-report-july-september-2024" rel="noreferrer noopener">trading higher on Friday.</a>
The company reported third-quarter adjusted earnings per share of $1.84, missing the analyst consensus of $1.95. Quarterly revenues of $2.56 billion topped the street view of $2.53 billion.
In the third quarter, sales fell by 0.8% organically. The firm performed well in Europe and Asia (excluding China) due to numerous product launches and favorable pricing.
Sales to domestic Chinese OEMs increased by 18%, outpacing their LVP growth of 8.5%. 
However, the firm struggled in China because of a negative mix, with sales of lower-safety models rising while higher-end models declined.
The company&#8217;s adjusted operating margin decreased to 9.3% from 9.4%.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/10/41399541/apple-iphone-16-sees-20-sales-surge-in-china-but-ai-absence-prompts-early-price-cuts" rel="noreferrer noopener">Apple iPhone 16 Sees 20% Sales Surge in China, But AI Absence Prompts Early Price Cuts</a>
&#8220;Light vehicle production was weak in the third quarter, declining by close to 5% globally. This was driven by a combination of inventory reductions, especially in the Americas and a high comparison base, especially in&nbsp;China,&#8221; said Mikael Bratt, President &amp; CEO.
The CEO indicated that, given recent sales trends and order intake, the company anticipates gaining more market share with domestic Chinese OEMs in the coming years.
Bratt also noted that negotiations for excess inflation compensation with customers have progressed as expected, although a few are still pending.
Outlook: Autoliv now expects full-year 2024 organic sales growth to be 1%, down from the previously anticipated 2%, <a href="https://www.benzinga.com/calendars/guidance">due to unfavorable market mix developments.</a>
With the seasonally strong fourth quarter remaining of the year, the company reaffirmed its guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
Price Action: ALV shares are trading higher by 5.69% to $99.24 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41388050/apples-3nm-push-boosts-taiwan-semis-q3-ai-revenue-set-to-triple-analyst" target="_blank" rel="noreferrer noopener">Apple&#8217;s 3nm Push Boosts Taiwan Semi&#8217;s Q3, AI Revenue Set To Triple: Analyst</a></li>
</ul>

Earnings

Guidance

Movers

General

Autoliv Surges Despite Mixed Q3 Results: Chinese Market Mix Drags  Performance

Piper Sandler analyst Adam Maeder reiterates Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Overweight and raises the price target from $495 to $538.

Reiteration

ISRG

Piper Sandler Reiterates Overweight on Intuitive Surgical, Raises Price Target to $538

Canaccord Genuity analyst Kingsley Crane maintains BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) with a Hold and raises the price target from $2.7 to $2.8.

Canaccord Genuity Maintains Hold on BlackBerry, Raises Price Target to $2.8

LYFT

Lyft Option Alert: 1,000 Contracts Of Oct 25 $14 Calls Swept Near The Ask At $0.26; Open Interest 2,062; Stock At $13.75 Ahead Of 11/6 Earnings

Piper Sandler analyst Matt O'Brien reiterates Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $200 to $225.

Piper Sandler Reiterates Overweight on Penumbra, Raises Price Target to $225

Alliance Global Partners initiates coverage on Global Self Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SELF#NASDAQ">SELF</a>) with a Buy rating and announces Price Target of $6.5.

Initiation

SELF

Alliance Global Partners Initiates Coverage On Global Self Storage with Buy Rating, Announces Price Target of $6.5

At the <a href="https://www.benzinga.com/events/">Benzinga Cannabis Capital Conference</a>, actor and cannabis advocate Jim Belushi emphasized the urgent need for cannabis policy reform, particularly around banking and taxation. As the founder of Belushi's Farm, he's not only invested in the cultivation of cannabis, but also in changing the way the plant is regulated and perceived in both the medical and recreational spaces.
Belushi pointed out the stark contrast between how cannabis and alcohol are treated in terms of taxation, using Illinois as an example. "Last year, they collected $474 million in cannabis taxes and $272 million in liquor taxes. And there are a lot more liquor stores and bars than dispensaries," Belushi said, highlighting the disproportionate burden placed on the cannabis industry.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Benzinga&#39;s Abbey Higginbotham chatted with <a href="https://twitter.com/JimBelushi?ref_src=twsrc%5Etfw">@JimBelushi</a> – Founder, Belushi&#39;s Farm <a href="https://t.co/sdlOi13UvO">pic.twitter.com/sdlOi13UvO</a>
&mdash; Benzinga (@Benzinga) <a href="https://twitter.com/Benzinga/status/1844800130496553364?ref_src=twsrc%5Etfw">October 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">Advocating For Change</h3>
Belushi has been a vocal proponent of cannabis reform, particularly the need to remove the plant from its classification as a Schedule I drug and to pass the Safe Banking Act, which would allow cannabis businesses more accessible access to financial services. "Let's get it off Schedule I. Let's pass the Banking Act. Let's bring down some regulations and over-taxation," he said.
He further stressed that cannabis offers a safer alternative to alcohol, saying, "Cannabis doesn't kill anybody. Alcohol does. It kills lots of people." This comparison underlines his argument for leveling the playing field between the two substances.
<h3 class="wp-block-heading">The Broader Impact of Cannabis Advocacy</h3>
Belushi also spoke about his broader advocacy for cannabis as a tool for healing, particularly in light of personal tragedies such as the loss of his brother John to an overdose. "Cannabis is a gentler alternative than opioids or overuse of alcohol to suppress anxiety and trauma," he said.
Through his platform and his involvement in the cannabis industry, Belushi is pushing for policy changes that not only benefit businesses but also help individuals find alternatives to harmful substances. As he noted, "People are suffering out there, and I think cannabis is the gentle way to help."
Belushi's continued efforts in the public and political arenas demonstrate his commitment to cannabis as more than just a business—it's a movement for broader social change.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Don't miss your chance to be part of Cannabis Market Spotlight: California in Anaheim on Nov. 12. Whether you want to connect with industry leaders, explore investment opportunities, or gain the latest insights into California's cannabis market, this event has it all.&nbsp;<a href="https://cannabismarketspotlight.com/california/anaheim-november-12/" target="_blank" rel="noreferrer noopener">Secure your spot today!</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free.&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe?_gl=1&#x2A;1ajl6va&#x2A;_gcl_au&#x2A;NjI5OTQ1MTM5LjE3Mjc5MzA5MjI.&#x2A;_ga&#x2A;MTAyOTE3MTY5OC4xNzI3OTMwOTIy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcyODkxMjAzOS41LjEuMTcyODkxMjEyMC4wLjAuMA.." target="_blank" rel="noreferrer noopener">Subscribe</a>&nbsp;to our newsletter here. You can't afford to miss out if you're serious about the business.
Jim Belushi speaks at the Benzinga Cannabis Capital Conference. Photo by Wendy Davis.

Cannabis

Politics

Events

Exclusives

Interview

EXCLUSIVE: Jim Belushi Speaks Out On Marijuana Reform, Says 'Cannabis Doesn't Kill Anybody, Alcohol Does'

UBS analyst Lloyd Byrne maintains Suncor Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SU#TSX">SU</a>) with a Buy and lowers the price target from C$63 to C$61.

TSX:SU

UBS Maintains Buy on Suncor Energy, Lowers Price Target to C$61

Piper Sandler analyst Matt Farrell reiterates Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Overweight and raises the price target from $800 to $840.

Piper Sandler Reiterates Overweight on Netflix, Raises Price Target to $840

RBC Capital analyst Jon Arfstrom maintains Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) with a Sector Perform and raises the price target from $73 to $83.

TCBI

RBC Capital Maintains Sector Perform on Texas Capital Bancshares, Raises Price Target to $83

<a href="https://www.benzinga.com/personal-finance/24/10/41335504/billionaire-mark-cuban-warns-when-you-win-the-lottery-never-invest-stick-it-in-the-bank-and-live">Mark Cuban may be worth billions</a> today, but it wasn't always that way. Cuban was once so broke he couldn't even scrape together the $200 needed to open a bank account. This personal anecdote was shared during the latest episode of Shark Tank, where Cuban reflected on his early days while hearing a pitch from Spare, a virtual ATM network aimed at the underbanked.
"When I was broke and sleeping on the couch, I couldn't open a bank account. You needed $200," Cuban explained, before committing $500,000 to the startup.
Don't Miss:
<ul>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a></li>
</ul>
Cuban's journey from couch-surfing to billionaire status is well-known, but the details offer insight into the <a href="https://www.benzinga.com/startups/24/10/41359639/it-was-amazing-says-mark-cuban-of-his-80s-ponzi-scheme-that-got-him-through-college-made-sure-his-fr">grit that powered his rise</a>. Born in Pittsburgh, Cuban grew up in a working-class family. He started a business early as a teenager, reselling baseball cards, stamps and coins. But not everyone believed in his potential. "People thought I might go work at a mill," he said. "My mom even wanted me to learn how to lay carpet."
See Also: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
After graduating from Indiana University, Cuban arrived in Dallas with just $60 in his pocket. He <a href="https://www.benzinga.com/personal-finance/24/08/40442345/mark-cuban-says-he-drove-cars-that-cost-200-with-holes-in-the-floorboard-and-lived-off-mac-and-c">shared a small apartment with five other guys</a>, sleeping on the floor or couch and worked as a bartender to make ends meet. Cuban's initial career stints didn't go smoothly either; he said he quit or was fired from three jobs in a row.
But then he found his footing in technology. "When I started working with computers, I realized I could go hours without even noticing time passing. That's when I knew I had found something I loved," he shared in a previous episode of Shark Tank. Cuban's tech passion eventually led him to launch MicroSolutions, which he sold for $6 million in 1990.
Trending: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
Cuban's next big break came in 1995 when he and Todd Wagner launched Broadcast.com, an online streaming service born out of their desire to listen to Indiana Hoosiers games from Texas. Yahoo bought the company in 1999 for $5.7 billion in stock.
"Nobody had high hopes for me," Cuban reflected. "But I was a hustler." His story, from struggling to open a bank account to becoming a billionaire, shows how far determination – and a little tech savvy – can go.
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
When you hear about a self-made billionaire, there's usually a moment when you're bracing for that "Surprise!" – the part where a rich relative swoops in with a hefty check. After all, real life doesn't usually involve fairy godmothers.&nbsp;
But in Cuban's tale, there's no twist, no secret benefactor. His story reads like a bona fide rags-to-riches saga, where every dollar was earned the hard way. No hidden chapters, no magical shortcuts – just a <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">relentless grind</a> that turned into a $5 billion net worth.
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>

Personal Finance

Mark Cuban Was So Broke He Didn't Even Have $200 Needed To Open A Bank Account And Now He's Worth Billions – 'Nobody Had High Hopes For Me'

MetroCity Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCBS#NASDAQ">MCBS</a>) reported quarterly earnings of $0.65 per share which met the analyst consensus estimate. The company reported quarterly sales of $36.904 million which beat the analyst consensus estimate of $36.200 million by 1.94 percent. This is a 36.40 percent increase over sales of $27.056 million the same period last year.

Earnings Beats

METROCITY BANKSHARES INC by MetroCity Bankshares Inc.

MCBS

MetroCity Bankshares Q3 2024 GAAP EPS $0.65, Inline, Sales $36.904M Beat $36.200M Estimate

OncoCyte GAAP EPS of -$0.36 beats by $0.19, revenue of $0.1M misses by $0.21M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
OncoCyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocx-stock-quote/">OCX</a>) just reported results for the second quarter of 2024.<ul><li>OncoCyte reported earnings per share of -36 cents. This was above the analyst estimate for EPS of -56 cents.</li><li>The company reported revenue of $104,000.</li><li>This was 67.50% worse than the analyst estimate for revenue of $320,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ocx-stock-earnings-oncocyte-for-q2-of-2024/">OCX Stock Earnings: OncoCyte Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OCX Stock Earnings: OncoCyte Beats EPS, Misses Revenue for Q2 2024

OncoCyte (OCX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham ...

OncoCyte's Growth Potential and Strategic Positioning Bolster Buy Rating

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

In a report released yesterday, Mark Massaro from BTIG reiterated a Hold rating on OncoCyte (OCX – Research Report). The company's shares closed ye...

BTIG Sticks to Their Hold Rating for OncoCyte (OCX)

Oncocyte gains 6% on $10.2M private placement

The latest update is out from OncoCyte ( ($OCX) ). Oncocyte Corporation has announced a private sale of over 3.4 million shares at $2.948 each to a...

OncoCyte Secures Funding Through Private Share Sale

In a report released today, Michael Matson from Needham reiterated a Buy rating on OncoCyte (OCX – Research Report), with a price target of $4.25. ...

OncoCyte's Strategic Shift and Market Potential Justify Buy Rating

An update from OncoCyte ( ($OCX) ) is now available. In a significant show of participation, holders of over 64% of voting shares attended a virtua...

Comments

OncoCyte

Notizie

Ultime notizie per OncoCyte (NASDAQ:OCX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO